AU2006300046A1 - Leucine rich composition - Google Patents

Leucine rich composition Download PDF

Info

Publication number
AU2006300046A1
AU2006300046A1 AU2006300046A AU2006300046A AU2006300046A1 AU 2006300046 A1 AU2006300046 A1 AU 2006300046A1 AU 2006300046 A AU2006300046 A AU 2006300046A AU 2006300046 A AU2006300046 A AU 2006300046A AU 2006300046 A1 AU2006300046 A1 AU 2006300046A1
Authority
AU
Australia
Prior art keywords
composition
composition according
carbohydrates
acid
proteinaceous matter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006300046A
Other languages
English (en)
Other versions
AU2006300046A2 (en
Inventor
Robert Johan Joseph Hageman
Johannes Adrianus Cornelis Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of AU2006300046A1 publication Critical patent/AU2006300046A1/en
Publication of AU2006300046A2 publication Critical patent/AU2006300046A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
AU2006300046A 2005-10-12 2006-10-11 Leucine rich composition Abandoned AU2006300046A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05077339.9 2005-10-12
EP05077339 2005-10-12
EP05077579.0 2005-11-11
EP20050077579 EP1774973A1 (en) 2005-10-12 2005-11-11 Leucine rich composition
PCT/NL2006/000515 WO2007043870A1 (en) 2005-10-12 2006-10-11 Leucine rich composition

Publications (2)

Publication Number Publication Date
AU2006300046A1 true AU2006300046A1 (en) 2007-04-19
AU2006300046A2 AU2006300046A2 (en) 2008-05-08

Family

ID=36228553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006300046A Abandoned AU2006300046A1 (en) 2005-10-12 2006-10-11 Leucine rich composition

Country Status (12)

Country Link
US (1) US20080275120A1 (enExample)
EP (2) EP1774973A1 (enExample)
JP (2) JP2009511576A (enExample)
CN (1) CN101325951A (enExample)
AU (1) AU2006300046A1 (enExample)
BR (1) BRPI0617358A2 (enExample)
CA (1) CA2625819A1 (enExample)
IL (1) IL190671A0 (enExample)
MX (1) MX2008004734A (enExample)
RU (1) RU2428977C2 (enExample)
WO (1) WO2007043870A1 (enExample)
ZA (1) ZA200803856B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2009157759A1 (en) * 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
ITMI20081405A1 (it) * 2008-07-29 2010-01-30 Velleja Res Srl Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011119023A1 (en) * 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
DK2409695T3 (en) 2010-07-05 2018-05-28 Beth Israel Deaconess Medical Ct Inc SN-2-MONOACYLGYLYCEROLS AND LIPID MALABSORPTION
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物
JP2014519483A (ja) * 2011-04-18 2014-08-14 ネステク ソシエテ アノニム α−ヒドロキシイソカプロン酸を含有する栄養組成物
SG11201507390SA (en) * 2013-03-14 2015-10-29 Abbott Lab Treatment of insulin resistance associated with prolonged physical inactivity
CA2914811C (en) 2013-06-10 2020-10-27 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3015860B1 (fr) * 2013-12-30 2019-08-16 Pronokal Health Group, Sociedad Limitada Composition alimentaire de regime pour diminuer l'inflammation de bas grade a court et long terme comprenant de l'acide docosahexaenoique
CN105769844B (zh) * 2016-05-25 2019-01-11 天津嘉氏堂医美科技有限公司 一种含精氨酸的组合物及制剂
JP7351617B2 (ja) * 2016-09-09 2023-09-27 味の素株式会社 認知症またはうつ状態の予防または改善用組成物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
WO2019190306A1 (en) 2018-03-27 2019-10-03 N.V. Nutricia Insulin control in overweight or obese adult during life time intervention
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
PL4061399T3 (pl) 2019-11-20 2024-05-20 Arla Foods Amba Działanie insulinotropowe i glukagonotropowe beta-laktoglobuliny
CN113519850A (zh) * 2020-04-13 2021-10-22 内蒙古蒙牛乳业（集团）股份有限公司 肿瘤全营养乳剂、其制备方法和用途
CN114159422B (zh) * 2021-09-29 2023-02-28 北京天赋神奇科技有限公司 一种含镁水溶性欧米伽3脂肪酸在促进小肠吸收能力中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
US6890571B2 (en) * 2002-05-14 2005-05-10 National Starch And Chemical Investment Holding Corporation Slowly digestible starch product
CN100469361C (zh) * 2002-06-19 2009-03-18 纽迪希亚公司 治疗或预防哺乳动物遭受代谢作用压力时的分解代谢或刺激性合成代谢的方法及组合物
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7037522B2 (en) * 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
ATE397453T1 (de) * 2003-06-30 2008-06-15 Nestec Sa Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz
NZ552706A (en) * 2004-07-19 2011-01-28 Nutricia Nv Use of aspartate for regulating glucose levels in blood
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition

Also Published As

Publication number Publication date
ZA200803856B (en) 2009-04-29
EP1945199A1 (en) 2008-07-23
CN101325951A (zh) 2008-12-17
BRPI0617358A2 (pt) 2011-07-26
AU2006300046A2 (en) 2008-05-08
EP1774973A1 (en) 2007-04-18
CA2625819A1 (en) 2007-04-19
JP2009511576A (ja) 2009-03-19
IL190671A0 (en) 2008-11-03
MX2008004734A (es) 2008-10-23
WO2007043870A1 (en) 2007-04-19
US20080275120A1 (en) 2008-11-06
JP2013139470A (ja) 2013-07-18
RU2428977C2 (ru) 2011-09-20
RU2008118341A (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
US20080275120A1 (en) Leucine rich composition
Adams et al. Insulinotropic effects of whey: mechanisms of action, recent clinical trials, and clinical applications
ES2582002T3 (es) Composición nutricional para mejorar el sistema inmunitario de los mamíferos
US9950013B2 (en) Nutritional composition for improving muscle function and daily activity
USRE40849E1 (en) Method of treatment of glutathione deficient mammals
CN101426513B (zh) 含有肽作为有效成分的组合物
CN102665736A (zh) 用于刺激肌肉蛋白合成的低热量高蛋白营养组合物
CN101370396A (zh) 用于改善膜组成的包括多不饱和脂肪酸的组合物
JP2009511576A5 (enExample)
JP2021506230A (ja) オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
WO2011021938A2 (en) Regulating the amino acid pool used for the acute-phase protein synthesis
CN102458449B (zh) 乳铁蛋白和成人和/或老人的肠神经元健康
CN1984571A (zh) 提高哺乳动物营养物利用的方法和其中使用的组合物
US20250381227A1 (en) Agglomerates of soluble whey protein aggregates and medical uses thereof
WO2006070874A1 (ja) 低酸素応答促進剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 APR 2008

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application